Europäische Union - Englisch - EMA (European Medicines Agency)

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. , treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).,

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

amgen inc - darbepoetin alfa (unii: 15uq94pt4p) (darbepoetin alfa - unii:15uq94pt4p) - darbepoetin alfa 10 ug in 0.4 ml - aranesp is indicated for the treatment of anemia due to chronic kidney disease (ckd), including patients on dialysis and patients not on dialysis. aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. aranesp has not been shown to improve quality of life, fatigue, or patient well-being. aranesp is not indicated for use: •       in patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. •       in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. •       in patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. •       as a substitute for rbc transfusions in patients who require immediate correction o

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 40000 iu/ml - injection, solution - excipient ingredients: glycine; polysorbate 80; monobasic sodium phosphate; water for injections; dibasic sodium phosphate dihydrate; sodium chloride - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the prevention and treatment of anaemia in adult patients with non-myeloid malignancies, where anaemia is anticipated to develop and develops as a result of concomitantly administered chemotherapy. eprex is indicated to decrease the need for transfusion in patients who will continue to receive concomitant chemotherapy for a minimum of two months. eprex is also indicated in adult patients with mild-to-moderate anaemia (haemoglobin >10 <=13 g/dl) scheduled for elective surgery with an expected moderate blood loss (2-4 units to 900 to 1800ml) to reduce exposure to allogenic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adults patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; sodium chloride; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium chloride; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; dibasic sodium phosphate; polysorbate 80; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: water for injections; monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; sodium chloride; polysorbate 80; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy